Compare HCSG & SLBT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HCSG | SLBT |
|---|---|---|
| Founded | 1976 | N/A |
| Country | United States | Taiwan |
| Employees | N/A | N/A |
| Industry | Assisted Living Services | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.5B |
| IPO Year | 1994 | 2025 |
| Metric | HCSG | SLBT |
|---|---|---|
| Price | $21.55 | $1.66 |
| Analyst Decision | Buy | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $22.67 | N/A |
| AVG Volume (30 Days) | ★ 477.0K | 79.3K |
| Earning Date | 04-22-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 52.83 | N/A |
| EPS | ★ 0.69 | N/A |
| Revenue | ★ $1,837,173,000.00 | N/A |
| Revenue This Year | $7.39 | N/A |
| Revenue Next Year | $5.22 | N/A |
| P/E Ratio | $31.12 | ★ N/A |
| Revenue Growth | ★ 7.08 | N/A |
| 52 Week Low | $15.26 | $1.71 |
| 52 Week High | $25.75 | $6.25 |
| Indicator | HCSG | SLBT |
|---|---|---|
| Relative Strength Index (RSI) | 39.16 | 30.96 |
| Support Level | $21.00 | N/A |
| Resistance Level | $23.05 | $3.36 |
| Average True Range (ATR) | 0.54 | 0.28 |
| MACD | -0.03 | -0.07 |
| Stochastic Oscillator | 37.36 | 5.98 |
Healthcare Services Group Inc is a provider of housekeeping and facility management services to the healthcare industry. The company manages and evaluates its operations in two reportable segments: Environmental Services segment includes housekeeping, management of clients' housekeeping departments, cleaning, disinfecting and sanitizing, laundry, bed linen, and uniform services, linen and other services; and Dietary Segment includes dietary department services, food purchasing, meal preparation, and providing dietitian consulting services. Its clients are nursing homes, retirement complexes, rehabilitation centers, and hospitals in the United States of America. The Environmental Services segment derives maximum revenue.
SL Science Holding Ltd is a biomedical company specialized in developing cellular and gene therapies advancing regenerative medicine and cancer treatment. It utilizes immune stem cells to target cancer and bovine-derived milk exosomes to regenerate damaged tissues, thus potentially offering expansive medical applications for its products. With proprietary technologies such as Armed-T and Gamma Delta T cells, as well as exosome applications in skincare and cancer recovery. It operates in three segments namely Exosome products, CD-19 Armed-T products, and GDT cell therapy products. It derives revenue from Exosome products segment.